Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines

Patients who search for a better treatment, an increased quality of life, or even a chance to preserve life itself may claim to have an interest in accessing investigational medicinal products (IMP), particularly when no validated treatment for their disease or condition exists. For many, awaiting t...

Full description

Saved in:  
Bibliographic Details
Authors: Pinxten, Wim (Author) ; Nys, Herman (Author) ; Dierickx, Kris (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2010
In: Journal of medical ethics
Year: 2010, Volume: 36, Issue: 12, Pages: 791-794
Online Access: Volltext (JSTOR)
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1816140457
003 DE-627
005 20230427161254.0
007 cr uuu---uuuuu
008 220908s2010 xx |||||o 00| ||eng c
024 7 |a 10.1136/jme.2010.036442  |2 doi 
035 |a (DE-627)1816140457 
035 |a (DE-599)KXP1816140457 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Pinxten, Wim  |e VerfasserIn  |4 aut 
245 1 0 |a Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines 
264 1 |c 2010 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Patients who search for a better treatment, an increased quality of life, or even a chance to preserve life itself may claim to have an interest in accessing investigational medicinal products (IMP), particularly when no validated treatment for their disease or condition exists. For many, awaiting the uncertain and time-consuming process of converting an IMP into an approved drug may not appear a realistic option, as prognoses may be grim and a dramatic outcome may seem hard to avert. Gaining access to an IMP, however, often proves to be a difficult enterprise with a highly uncertain outcome. In addition, the process of seeking access to IMP is surrounded by various ethical issues that will be explored in this article. This paper explores the ethical concerns in two potential tracks of seeking access to IMP for minors: on an individual basis, or collectively, as a patient organisation. In this discourse, several unique ethical and regulatory concerns related to the direct negotiation of access to IMP for minor patients are identified, with a focus on product safety, the recruitment of research subjects, the unnoticed entry of market mechanisms in the recruitment of research subjects, and the sidelining of third parties in the recruitment process. The paper concludes with a concise reflection on the way forward. The quest for access to investigational drugs is particularly relevant to paediatric practice, in which a significant share of the drugs prescribed has never been tested in children or labelled for use in the paediatric population. 
700 1 |a Nys, Herman  |e VerfasserIn  |4 aut 
700 1 |a Dierickx, Kris  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 36(2010), 12, Seite 791-794  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:36  |g year:2010  |g number:12  |g pages:791-794 
856 |3 Volltext  |u http://www.jstor.org/stable/25764319  |x JSTOR 
856 4 0 |u https://doi.org/10.1136/jme.2010.036442  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/36/12/791.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
936 u w |d 36  |j 2010  |e 12  |h 791-794 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 418559433X 
LOK |0 003 DE-627 
LOK |0 004 1816140457 
LOK |0 005 20220908053527 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-02#C1B0DDB1908E6B60E09E1E24C3496E2C45D2EFE5 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/25764319 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1  |b inherited from superior work 
ORI |a SA-MARC-ixtheoa001.raw